| Eligibility |
Inclusion Criteria:
- Females or Males, 18 to 55 years of age (inclusive).
- Fitzpatrick Skin Type I - VI.
- Tattoos containing black/blue ink alone or in combination with other colors. No
tribal, scarred, high-ink density, or highly colorful tattoos.
- Target tattoos older than 1 year.
- Must be able to read, understand and sign the Informed Consent Form.
- Must be willing and able to adhere to the treatment and follow-up schedule and
post-treatment care instructions.
- Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun
exposure and use an approved sunscreen of SPF 50 or higher on the treated area
starting 2 to 4 weeks before the treatment and/or every day for the duration of the
study, including the follow-up period.
- Willing to use hydroquinone approximately 4 weeks pre-treatment and post-treatment if
required by Investigator.
- Willingness to have digital photographs taken of the treated area.
- Agree not to undergo any other procedure(s) for the tattoo removal during the study.
- Post-menopausal or surgically sterilized, or using a medically acceptable form of
birth control at least 3 months prior to enrollment and during the entire course of
the study.
Exclusion Criteria:
- Participation in a study of another device or drug within 6 months prior to enrollment
or during the study.
- History of allergic reaction to pigments following tattooing.
- Presence of double tattoo in the treatment area or presence of tribal, scarred,
high-ink density, or highly colorful single tattoos.
- History of allergy to local anesthetics.
- History of allergy to topical antibiotics.
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large
moles.
- Pregnant and/or breastfeeding.
- Having an infection, dermatitis or a rash in the treatment area.
- Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,
e.g., uncontrolled hypertension.
- Suffering from coagulation disorders or taking prescription anticoagulation
medications.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- History of immunosuppression/immune deficiency disorders or currently using
immunosuppressive medications.
- History of vitiligo, eczema, or psoriasis.
- History of connective tissue disease, such as systemic lupus erythematosus or
scleroderma.
- History of seizure disorders due to light.
- Any use of medication that is known to increase sensitivity to light according to the
Investigator's discretion.
- History of herpes simplex and/or herpes zoster (shingles).
- History of radiation to the treatment area or undergoing systemic chemotherapy for the
treatment of cancer.
- History of pigmentary disorders, particularly tendency for hyper- or
hypo-pigmentation.
- Systemic use of corticosteroid within 12 months of study participation.
- Use of oral isotretinoin within 12 months of study participation and topical use of
isotretinoin within 6 months on the treated area.
- Anytime in life, having have used gold therapy (gold salts) for disorders such as
rheumatologic disease or lupus.
- Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
during the study.
- Current smoker or history of smoking within 6 months of study participation.
- As per the Investigator's discretion, any physical or mental condition which might
make it unsafe for the subject to participate in this study.
|
